HIV AIDS

Your daily dose of the clinical news you may have missed.

IDWeek 2023. New study found just slightly more than half of prescriptions for cabotegravir for HIV PrEP resulted in at least 1 injection, suggesting limitations in use and access to the injectable HIV integrase inhibitor.

IDWeek 2023: In a large cohort of people living with HIV, those switching from oral ART to long acting CAB+RPV were more than 4x as likely to adhere to the regimen.

Approved for persons with HIV with undetectable VL, CAB+RPV LA may also be appropriate for those with VL ≥50 copies when the therapy is initiated, according to new findings.

IDWeek 2023: Leading physician scientists will headline plenary sessions and named lectureships on topics ranging from antibiotic stewardship to artificial intelligence.

The USPSTF particularly emphasizes effective communication with patients, including adherence support and calls for reducing barriers to PrEP for racial, ethnic, and other minority groups.

Patient Care Guideline Toplines summarize newly revised and updated clinical recommendations from professional societies for convenient, at-a-glance review.

Lenacapavir is the first of a new class of antiretrovirals, and it is indicated for persons with multidrug resistance, intolerance, or safety considerations.

New data showed a sharp drop in HIV tests administered in health care and non-health care settings from 2019 to 2020—primarily among persons disproportionately affected by HIV.

Persons with HIV now have the option to forego initiation of the long-acting injectable with oral formulations of the medications, according to a statement from Viiv Healthcare.

New study suggests HIV-1 infection is more virulent when transmitted through heterosexual penile-vaginal intercourse than through anal intercourse between men who have sex with men due to transmission bottlenecks.

The CDC update recommends that clinicians advise all sexually active patients about PrEP and includes a new section on prescribing injectable bimonthly cabotegravir.

Get 90% of all HIV-infected persons diagnosed, get 90% of them on ART, and get 90% of those on ART “undetectable.” Are we there yet?

The AAP updated its guidance to recommend routine HIV screening at least once in all adolescents aged ≥15 years and at-risk youth be rescreened annually.

Nearly 25% of patients with HIV who use antiretroviral therapy will reach 65 years of age or older by 2030, researchers projected in a new analysis.

IDWeek 2021: Despite declining mortality rates among patients with HIV in the past 2 decades, a new study finds significant disparities in gender and race.

Viral-load monitoring rates decreased and clinic visits declined overall despite an increase in use of telehealth.

Patients with HIV had a 14% higher risk of sudden cardiac death than those without HIV, according to a large analysis of US veterans.

Rodger MacArthur, MD, was in his HIV clinic last week and queried his COVID-19 vaccine-hesitant/resistant patients about their reasons. The refrain was familiar and discouraging.

Vaccines from both companies were significantly effective against COVID-19 and show promise against variants from the UK and South Africa.

Cabotegravir and rilpivirine, injectable formulation is administered once-weekly, reducing treatment days for adults with HIV from 365 to 12.

The FDA announced October 3 approval of Descovy®, making it the second drug to receive indication for HIV pre-exposure prophylaxis.

The underpinnings of the global HIV and STI epidemics are inextricable. A new report looks at combined solutions. We offer highlights.

Highlights: The first liquid solution of colchicine for prophylaxis of gout, the first generic version of Advair Diskus, and 8 more new and approved drugs.

A first-of-its-kind study found that among cirrhosis patients with and without HIV-coinfection, liver function improved >50% in each cohort.